Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Longitudinal Research02:20

Longitudinal Research

12.3K
Sometimes we want to see how people change over time, as in studies of human development and lifespan. When we test the same group of individuals repeatedly over an extended period of time, we are conducting longitudinal research. Longitudinal research is a research design in which data-gathering is administered repeatedly over an extended period of time. For example, we may survey a group of individuals about their dietary habits at age 20, retest them a decade later at age 30, and then again...
12.3K
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

56
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
56
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

271
Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
271
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

119
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
119
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

124
DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
124
Longitudinal Studies01:26

Longitudinal Studies

228
Longitudinal studies are also widely used in other medical and social science fields. For instance, in cardiovascular research, they can monitor patients' health over decades to identify risk factors for heart disease, such as high cholesterol or smoking, and evaluate the long-term effectiveness of preventive measures. Similarly, in mental health studies, researchers might follow individuals from adolescence into adulthood to understand the development and progression of conditions like...
228

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Computer Assisted Nodule Analysis and Risk Yield Outcomes May be Associated with Recurrence after Stereotactic Body Radiation Therapy in Clinical Stage I Non-Small-Cell Lung Cancer.

Clinical lung cancer·2025
Same author

Emergency Room, Cardiology, and Preoperative Clinics Represent the Most Visited Departments by Lung Cancer Screening-eligible Patients.

The Annals of thoracic surgery·2025
Same author

Computer Assisted Nodule Analysis and Risk Yield is Associated With Occult Lymph Node Status in Clinical Stage I-IIA Lung Adenocarcinoma Undergoing Resection.

Clinical lung cancer·2024
Same author

Enhanced Recovery With Aggressive Ambulation Decreases Length of Stay in Lung Cancer Surgery.

Clinical lung cancer·2024
Same author

Does Play-Based Learning Support Children's Everyday Resiliency? A Cross-Case Analysis of Parents' and Kindergarten Teachers' Perceptions of Play-Based Learning as a Precedent to Young Children's Coping During the Pandemic-Affected 2020-2021 School Year.

Children (Basel, Switzerland)·2024
Same author

Radiomic score is prognostic in clinical stage I lung adenocarcinoma ≤2 cm undergoing surgery.

Journal of thoracic disease·2024

Related Experiment Video

Updated: Sep 5, 2025

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases
11:08

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Published on: June 22, 2012

16.1K

Ten-year longitudinal analysis of hydroxyurea implementation in a pediatric sickle cell program.

Vivian Phan1, Ju Ae Park2, Robin Dulman1

  • 1Pediatric Specialists of Virginia, Fairfax, Virginia, USA.

European Journal of Haematology
|July 11, 2022
PubMed
Summary

Hydroxyurea (HU) significantly improves sickle cell anemia (SCA) outcomes by increasing hemoglobin and fetal hemoglobin levels. This treatment is feasible, effective, and sustainable for pediatric SCA patients, reducing hospitalizations and transfusions.

Keywords:
MTD (maximal-tolerated dose)fetal hemoglobinhydroxyurea implementationlongitudinal datapediatric sickle cell

More Related Videos

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.8K
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

19.6K

Related Experiment Videos

Last Updated: Sep 5, 2025

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases
11:08

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Published on: June 22, 2012

16.1K
A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.8K
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

19.6K

Area of Science:

  • Hematology
  • Pediatric Medicine
  • Pharmacology

Background:

  • Sickle cell anemia (SCA) is a debilitating genetic blood disorder.
  • Hydroxyurea (HU) is a proven treatment for SCA but remains underutilized.
  • Effective implementation strategies for HU in pediatric SCA are needed.

Purpose of the Study:

  • To evaluate the impact of a uniform hydroxyurea (HU) prescription protocol on clinical and laboratory outcomes in pediatric patients with sickle cell anemia (SCA).
  • To assess the feasibility, effectiveness, and sustainability of HU treatment in a real-world pediatric setting.

Main Methods:

  • A prospective, longitudinal study analyzed data from 2009-2019 for 1222 HU-eligible pediatric SCA patients.
  • Hydroxyurea was prescribed regardless of symptoms to all patients aged ≥9 months, dosed to maximum tolerated dosing (MTD) targeting 30% fetal hemoglobin (Hgb F).
  • Outcomes including hemoglobin (Hgb), Hgb F, hospitalizations, transfusions, and emergency department (ED) visits were tracked in 2-year intervals.

Main Results:

  • Hydroxyurea usage increased from 33% to 93% from 2009-2011 to 2017-2019.
  • Average Hgb increased from 8.3 to 9.8 g/dL (p<0.0001), and average Hgb F rose from 13% to 26% (p<0.0001).
  • Hospitalizations decreased from 0.71 to 0.2 admissions/person-year, and transfusions decreased from 0.4 to 0.05 transfusions/person-year. Treat-and-release ED visits remained unchanged.

Conclusions:

  • Uniform hydroxyurea (HU) prescription and close monitoring in pediatric sickle cell anemia (SCA) patients lead to significant improvements in laboratory and clinical outcomes.
  • These improvements are achievable within 2 years and are sustainable over longer periods.
  • Rigorous implementation of HU is feasible and effective in a pediatric SCA population, reducing disease burden.